Zevra Therapeutics, Inc.
ZVRA
$8.33
-$0.06-0.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.70% | 26.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.70% | 26.86% | |||
| Cost of Revenue | -90.00% | 820.37% | |||
| Gross Profit | 83.86% | -29.15% | |||
| SG&A Expenses | -18.51% | 6.33% | |||
| Depreciation & Amortization | -80.51% | 0.06% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -42.63% | 48.31% | |||
| Operating Income | 133.60% | -129.93% | |||
| Income Before Tax | -101.27% | 4,111.79% | |||
| Income Tax Expenses | -119.69% | 86.04% | |||
| Earnings from Continuing Operations | -100.73% | 2,510.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -100.73% | 2,510.68% | |||
| EBIT | 133.60% | -129.93% | |||
| EBITDA | 142.47% | -187.58% | |||
| EPS Basic | -100.77% | 2,310.82% | |||
| Normalized Basic EPS | 91.52% | -556.11% | |||
| EPS Diluted | -100.81% | 2,254.28% | |||
| Normalized Diluted EPS | 91.28% | -538.01% | |||
| Average Basic Shares Outstanding | 2.14% | 1.27% | |||
| Average Diluted Shares Outstanding | -0.66% | 4.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||